Integrated Approach to Ensuring Viral Safety of Cell and Gene Therapy Products
Posted on May 16, 2019
Mark Plavsic,
Chief Technology Officer,
Lysogene
Introduction Use of continuous cell lines in the manufacture of biological therapeutic products such as vaccines, recombinant proteins and monoclonal antibodies is associated with the concomitant risk of process/product contamination with endogenous retroviruses, latent viruses, or new and emerging ...
To read the full article and other articles in this issue, please register for a free account or log in.
We will not sell or give your information to a third party. See our Privacy Policy
Subscribe to our FREE newsletter and WEBINAR UPDATES
We will not sell or give your information to a third party. See our Privacy Policy
